Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging

被引:34
|
作者
Hodel, Jerome [1 ,2 ,5 ,7 ]
Outteryck, Olivier [1 ,3 ]
Dubron, Celine [1 ,2 ]
Dutouquet, Bastien [1 ,2 ]
Benadjaoud, Mohamed Amine [8 ]
Duhin, Emeline [1 ,3 ]
Verclytte, Sebastien [4 ]
Zins, Marc [9 ]
Luciani, Alain [6 ,7 ]
Rahmouni, Alain [6 ,7 ]
Pruvo, Jean-Pierre [1 ,2 ]
Vermersch, Patrick [1 ,3 ]
Leclerc, Xavier [1 ,2 ]
机构
[1] Univ Lille, CHU Lille, Lille, France
[2] Hop Roger Salengro, Dept Neuroradiol, Rue Emile Laine, F-59037 Lille, France
[3] Hop Roger Salengro, Dept Neurol, Rue Emile Laine, F-59037 Lille, France
[4] Hop St Philibert, Dept Radiol, Lille, France
[5] Hop Univ Henri Mondor, AP HP, Dept Neuroradiol, Creteil, France
[6] Hop Univ Henri Mondor, AP HP, Dept Med Imaging, Creteil, France
[7] Univ Paris Est Creteil, Fac Med, Creteil, France
[8] CESP Ctr Res Epidemiol & Populat Hlth, INSERM, U1018, Radiat Epidemiol Team, Villejuif, France
[9] Hop St Joseph, Dept Radiol, F-75674 Paris, France
关键词
JC VIRUS-INFECTION; MULTIPLE-SCLEROSIS; PML; DISEASE; PATTERN; PATIENT;
D O I
10.1148/radiol.2015150673
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine diagnostic precision with magnetic resonance (MR) imaging of the brain, the most predictive MR imaging features, and the added value of comparison with previous data for the diagnosis of asymptomatic progressive multifocal leukoencephalopathy (PML) associated with natalizumab (NTZ). Materials and Methods: This retrospective study was approved by the institutional review board, and written informed consent was obtained. Eleven consecutive patients with multiple sclerosis (MS) who had received a definitive diagnosis of asymptomatic NTZ-associated PML (NTZ PML, 18 brain lesions) underwent 3-T MR imaging. The control group included 40 patients with MS but without PML who were treated with NTZ. Three readers independently performed blinded analysis of MR images. First, the readers were asked to detect NTZ PML lesions without comparing current images with previously obtained MR imaging data by evaluating MR images for the following features: U fiber and/or cortex involvement, lesion signal intensity and borders, and occurrence of punctate lesions. Second, they reassessed NTZ PML lesions with all the previous MR imaging data available. Diagnostic precision with MR imaging was assessed with and without comparison with previously obtained data. Logistic regression analyses were performed to identify the association of MR imaging features with NTZ PML. Results: Overall interobserver agreement was good (k = 0.76; 95% confidence interval [CI]: 0.71, 0.81). Hyperintensity on diffusion-weighted images and involvement of U fibers were the most predictive features (odds ratio, 33.7; 95% CI: 4.9, 229.7 [P < .0001] and odds ratio, 8.7; 95% CI: 1.2, 61.4 [P = .03], respectively), while punctate lesions were exclusively observed in patients with NTZ PML. Comparison with previous MR imaging data improved specificity of MR imaging for the detection of NTZ PML lesions (from 88% to 100%, P = .05). Conclusion: Recognition of the most predictive imaging features and comparison with previous MR imaging data may facilitate the detection of asymptomatic NTZ PML. (C) RSNA, 2015
引用
收藏
页码:863 / 872
页数:10
相关论文
共 50 条
  • [1] Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab
    McGovern, Eavan M.
    Hennessy, Michael J.
    JOURNAL OF NEUROLOGY, 2013, 260 (02) : 665 - 667
  • [2] Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab
    Eavan M. Mc Govern
    Michael J. Hennessy
    Journal of Neurology, 2013, 260 : 665 - 667
  • [3] Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
    Wenning, Werner
    Haghikia, Aiden
    Laubenberger, Joerg
    Clifford, David B.
    Behrens, Peter F.
    Chan, Andrew
    Gold, Ralf
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (11): : 1075 - 1080
  • [4] Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
    Mancini, Nicasio
    Clementi, Massimo
    Burioni, Roberto
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09): : 871 - 872
  • [5] TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy
    Mahler, Christoph
    Schumacher, Adrian-Minh
    Unterrainer, Marcus
    Kaiser, Lena
    Hollbacher, Thomas
    Lindner, Simon
    Havla, Joachim
    Ertl-Wagner, Birgit
    Patzig, Maximilian
    Seelos, Klaus
    Neitzel, Julia
    Maurer, Matthias
    Krumbholz, Markus
    Metz, Imke
    Bruck, Wolfgang
    Stadelmann, Christine
    Merkler, Doron
    Gass, Achim
    Milenkovic, Vladimir
    Bartenstein, Peter
    Albert, Nathalie L.
    Kuempfel, Tania
    Kerschensteiner, Martin
    BRAIN, 2021, 144 : 2683 - 2695
  • [6] Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment
    Fabis-Pedrini, Marzena J.
    Xu, Wen
    Burton, Jason
    Carroll, William M.
    Kermode, Allan G.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2016, 25 : 145 - 147
  • [7] MR IMAGING IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
    GUILLEUX, MH
    STEINER, RE
    YOUNG, IR
    AMERICAN JOURNAL OF NEURORADIOLOGY, 1986, 7 (06) : 1033 - 1035
  • [8] Progressive multifocal leukoencephalopathy and natalizumab
    Hellwig, Kerstin
    Gold, Ralf
    JOURNAL OF NEUROLOGY, 2011, 258 (11) : 1920 - 1928
  • [9] Natalizumab and Progressive Multifocal Leukoencephalopathy
    Warnke, Clemens
    Menge, Til
    Hartung, Hans-Peter
    Racke, Michael K.
    Cravens, Petra D.
    Bennett, Jeffrey L.
    Frohman, Elliot M.
    Greenberg, Benjamin M.
    Zamvil, Scott S.
    Gold, Ralf
    Hemmer, Bernhard
    Kieseier, Bernd C.
    Stuve, Olaf
    ARCHIVES OF NEUROLOGY, 2010, 67 (08) : 923 - 930
  • [10] Natalizumab and progressive multifocal leukoencephalopathy
    Adelman, B
    Sandrock, A
    Panzara, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04): : 432 - 433